{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T03:45:51Z","timestamp":1785383151268,"version":"3.55.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Cyclin-dependent kinase 4\/6 inhibitors (CKIs), ribociclib, palbocilb and abemaciclib, have been approved in combination with endocrine therapy for the treatment of hormone receptor-positive and human epidermal growth factor 2-negative advanced or metastatic breast cancer. Severe dermatological adverse events are rare with these agents; however, they require direct recognition and management in order not to become life-threatening. Erythema multiforme (EM) belongs to a dermatopathic spectrum that includes immune-mediated, widespread hypersensitivity reaction, which occurs with varying degrees of severity and affects the skin and\/or the mucosa. We hereby present a case of ribociclib- and palbociclib-related EM. We sought to report this case given the implication of two agents from the same drug class in EM onset. We also aim to emphasize the breadth of mechanisms of actions of CKIs, with an impingement in the immune system as well, and the importance of promptly identifying and handling such skin toxicities.<\/jats:p>","DOI":"10.1093\/omcr\/omac116","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T12:19:22Z","timestamp":1669378762000},"source":"Crossref","is-referenced-by-count":7,"title":["Ribociclib and palbociclib-induced erythema multiforme: a case report"],"prefix":"10.1093","volume":"2022","author":[{"given":"Eleni","family":"Vrana","sequence":"first","affiliation":[{"name":"\u201cEuromedica\u201d General Clinic , Oncology Department, 54645 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Mylona","sequence":"additional","affiliation":[{"name":"Dermatologist, 55133 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattheos","family":"Bobos","sequence":"additional","affiliation":[{"name":"Microdiagnostics LP Pathology, , Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loukas","family":"Kontovinis","sequence":"additional","affiliation":[{"name":"\u201cEuromedica\u201d General Clinic , Oncology Department, 54645 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1048-2715","authenticated-orcid":false,"given":"Konstantinos","family":"Papazisis","sequence":"additional","affiliation":[{"name":"\u201cEuromedica\u201d General Clinic , Oncology Department, 54645 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"2022112510394239300_ref1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1365-4632.2011.05348.x","article-title":"Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist","volume":"51","author":"Sokumbi","year":"2012","journal-title":"Int J Dermatol"},{"key":"2022112510394239300_ref2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.cden.2013.07.001","article-title":"Erythema multiforme. a review of epidemiology, pathogenesis, clinical features, and treatment","volume":"57","author":"Samim","year":"2013","journal-title":"Dent Clin N Am"},{"key":"2022112510394239300_ref3","article-title":"Side effects of cdk4\/6 inhibitors in the treatment of hr+\/her2\u2212 advanced breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Yang","year":"2021","journal-title":"Ann Palliat Med"},{"key":"2022112510394239300_ref4","article-title":"Skin toxicities with cyclin-dependent kinase 4\/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA adverse event reporting system","author":"Raschi","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2022112510394239300_ref5","doi-asserted-by":"crossref","DOI":"10.5070\/D37V35W30D","article-title":"Herpes simplex virus (HSV)-associated erythema multiforme (HAEM): a viral disease with an autoimmune component","volume":"9","author":"Aurelian","year":"2003","journal-title":"Dermatol Online J"},{"key":"2022112510394239300_ref6","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-323-48551-7.00006-7","article-title":"Cutaneous reactions to drugs","author":"Lockwood","year":"2018","journal-title":"Drug Allergy Testing"},{"key":"2022112510394239300_ref7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1158\/1078-0432.CCR-18-1999","article-title":"To cycle or fight\u2014CDK4\/6 inhibitors at the crossroads of anticancer immunity","volume":"25","author":"Ameratunga","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2022112510394239300_ref8","doi-asserted-by":"crossref","first-page":"113676","DOI":"10.1016\/j.bcp.2019.113676","article-title":"Multiple effects of CDK4\/6 inhibition in cancer: From cell cycle arrest to immunomodulation","volume":"170","author":"Bonelli","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"2022112510394239300_ref9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40264-021-01071-1","article-title":"Emerging skin toxicities in patients with breast cancer treated with new cyclin-dependent kinase 4\/6 inhibitors: a systematic review","volume":"44","author":"Silvestri","year":"2021","journal-title":"Drug Saf"},{"key":"2022112510394239300_ref10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jdcr.2017.12.015","article-title":"Stevens-Johnson syndrome\u2013like eruption from palbociclib in a patient with metastatic breast cancer","volume":"4","author":"Karagounis","year":"2018","journal-title":"JAAD Case Rep"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2022\/11\/omac116\/47256156\/omac116.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2022\/11\/omac116\/47256156\/omac116.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T20:20:53Z","timestamp":1701462053000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omac116\/6845485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":10,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omac116","relation":{},"ISSN":["2053-8855"],"issn-type":[{"value":"2053-8855","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11]]},"published":{"date-parts":[[2022,11,1]]},"article-number":"omac116"}}